Primary source: European Medicines Agency (EMA)
The procedural advice includes refined timelines and structured interactions for pre-submission activities, mandating that marketing authorisation holders ensure their pharmacovigilance system summaries and RMPs align with new procedural expectations.
Compliance with the updated procedural guidelines is crucial for ensuring timely and effective submissions, avoiding potential delays caused by incomplete registrations in the OMS, which can obstruct the regulatory process.
Marketing Authorisation Holders (MAHs) and applicants must register new sites and organisations in the OMS before any regulatory submission and ensure alignment of their submission documents with the latest guidelines.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Updated guidance on pre-submission interaction requests and the inclusion of pharmacovigilance system summaries and Risk Management Plans (RMP) in the submission dossier. Refined timelines and procedural steps for the centralized marketing authorisation process.
MAHs and applicants must ensure that their PV system summary and RMP align with the latest procedural expectations outlined in this advice. PV operations and regulatory teams should review the updated interaction request forms and submission timelines to ensure timely and compliant MAA filings.
Delays in submissions if registration is not completed prior to pre- and post-authorisation submissions.
Mandatory registration in OMS prior to submissions
Facilitates guidance and regulatory advice to streamline the submission process.
Structured interactions during the pre-submission phase
Marketing Authorisation Holders (MAHs) and applicants must register new sites and organisations in the OMS before any regulatory submission and ensure alignment of their submission documents with the latest guidelines.
The EMA has updated its procedural advice for the centralised marketing authorisation process, detailing new requirements for pre-submission interactions and documentation, including pharmacovigilance system summaries and Risk Management Plans (RMPs). This includes mandatory registration in the Organisation Management Service (OMS) prior to regulatory submissions, which has been effective since November 1, 2021, and emphasizes the need for pre-submission meetings approximately seven months before application submission.
What changed: The procedural advice includes refined timelines and structured interactions for pre-submission activities, mandating that marketing authorisation holders ensure their pharmacovigilance system summaries and RMPs align with new procedural expectations.
Why it matters: Compliance with the updated procedural guidelines is crucial for ensuring timely and effective submissions, avoiding potential delays caused by incomplete registrations in the OMS, which can obstruct the regulatory process.
Practical implication: Marketing Authorisation Holders (MAHs) and applicants must register new sites and organisations in the OMS before any regulatory submission and ensure alignment of their submission documents with the latest guidelines.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
